Recombinant Aflibercept Biosimilar anticorps

N° du produit ABIN7795087

Cet anticorps anti-Aflibercept Biosimilar Monoclonal Souris (ABIN7795087) détecte spécifiquement Aflibercept Biosimilar dans FACS et in vivo. L’anticorps est réactif avec des échantillons de Humain.

Aperçu rapide pour Recombinant Aflibercept Biosimilar anticorps (ABIN7795087)

Antigène: Aflibercept Biosimilar

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Classe de qualité: Research Grade

Détail du produit

Expression System: Mammalian cells

Fonction: Aflibercept Biosimilar

Attributs du produit: What is research grade Aflibercept biosimilar? Research grade Aflibercept biosimilar has the same amino acid sequence as Aflibercept (trade name Eylea), a recombinant protein composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors fused with the Fc region of human immunoglobulin gamma 1 (IgG1). It inhibits vascular endothelial growth factor (VEGF), and is used in the treatment of macular edema following Central Retinal Vein Occlusion (CRVO) and neovascular Age-Related Macular Degeneration (AMD). Aflibercept is a dimeric glycoprotein with a molecular weight of 96.9 kilo Daltons ( kDa). Glycosylation adds its molecular weight to 115 kDa in total. Ziv-aflibercept (trade name Zaltrap) was developed as an injection for treatment of metastatic colorectal cancer.

Purification: Protein A or G affinity column

Pureté: >95 % by reducing SDS-PAGE

niveau d'endotoxine: < 1 EU per 1 mg of the protein by the LAL method

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: > 3 mg/mL

Stock: 4 °C,-20 °C

Stockage commentaire: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Détail du antigène

Antigène: Aflibercept Biosimilar

Classe de substances: Biosimilar